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Abstract
The muscular dystrophies are a diverse group
of inherited muscle disorders characterized by
progressive muscle weakness and wasting with
characteristic histologic abnormalities such as
degeneration, necrosis, and regeneration of mus-
cle fibers. With progress in molecular genetics
methods, new discoveries of dystrophin and
related molecules have dramatically changed the
understanding and diagnosis of a large group of
muscular dystrophy patients. Dystrophin and its
related molecular associates are tightly associat-
ed and form an essential cytoskeletal system
(dystrophin-glycoprotein complex) at the muscle
fiber surface membrane, which is critical for
maintaining the integrity of the sarcolemma and
muscle fibers. Deficiency of one of these sar-
colemmal proteins, including dystrophin, dystro-
glycans, sarcoglycans, and laminin-2, leads to
the breakdown and instability of muscle fibers
and to clinically observed progressive muscle
weakness. Identification of the molecular cause
of muscular dystrophies would allow a genetic
oriented classification and diagnosis using DNA
or protein analysis. However, definition of the
molecular pathogenesis of muscular dystrophies
has not been completely possible until now.
Future advances in this field should allow the
exact diagnosis and treatment of muscular dys-
trophies. 
Key words: muscular dystrophy, dystrophin-glyco-
protein complex (DGC), limb-girdle muscular dystro-
phy (LGMD), facioscapulohemeral dystrophy,
myotonic dystrophy
Introduction 
Muscular dystrophies are a diverse group of inherit-
ed muscle disorders characterized by progressive
muscle weakness and wasting with characteristic his-
tologic abnormalities such as degeneration, necrosis,
and regeneration of muscle fibers. Erb first introduced
the term “muscular dystrophy”in 1891.1 Hoverer,
these disorders have a wide range of clinical manifes-
tation, from a severe childhood-onset form that leads
to early death, to more benign adult forms that do not
affect life span and may cause only minimal disability.
Until recently, it has only been possible to classify
these disorders on the basis of their clinical presenta-
tion - for example, limb-girdle muscular dystrophy
(LGMD), facioscapulohumeral muscular dystrophy
(FSHD), Duchenne/Becker muscular dystrophy
(DMD/BMD), congenital muscular dystrophy (CMD),
distal myopathy, and myotonic dystrophy (DM). With
the application of advanced molecular genetic tech-
niques beginning in the 1980s, the dystrophin gene
was finally identified in 1985, and its protein product
(dystrophin) in 1987.2-4 Since then, using a variety of
increasingly sophisticated techniques, the genes and
gene products for many other muscle disorders have
been also identified.5
Identification of the molecular pathogenesis of mus-
cular dystrophies now allows for a new classification
and understanding based on a genetic or pathologic
process, as determined by DNA or protein analysis.
Table 1 presents a classification for which the genetic
cause has been identified, but not fully defined. With
the discovery of dystrophin deficiency as the cause of
both DMD and BMD, these forms have been classi-
fied as “dystrophinopathy”, which replaced the tradi-
tional term “Duchenne/Becker muscular dystrophy”.
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Table 1. Classification of the Muscular Dystrophies
Disease Inheritance Gene Mutation Protein
X-linked dystrophies
Duchenne/Becker XR   Xp21 Dystrophin
Emery-Dreifuss XR Xq28 Emerin
Limb-girdle muscular dystrophies(LGMD)
LGMD 1A AD 5q31 Myotilin
LGMD 1B AD 1q11-1 LaminA/C  
LGMD 1C AD 3p25 Calveolin-3
LGMD 1D AD 6q23 Calveolin-3
LGMD 1E AD 7q ?
LGMD1F AD 7q Filamin
LGMD 2A AR 15q15.1 Calapin-3
LGMD 2B AR 2p13 Dysferin
LGMD 2C AR 13q12 γ-sarcoglycan
LGMD 2D AR 17q12 α-sarcoglycan
LGMD 2E AR 4q12 β-sarcoglycan
LGMD 2F AR 5q33 δ-sarcoglycan
LGMD 2G AR 17q12 telethonin
LGMD 2H AR 9p31 E3-ubiquitine ligase
LGMD 2I AR 19q31 FKRP
LGMD 2J AR 2q31 titin
Congenital muscular dystrophies(CMD)
(With CNS involvement)
Fukuyama CMD AR 9q31-33 Fukutin
Walker-Warburg symdrome AR 9q34 POMT1 
Muscle-Eye-Brain CMD AR 1 p3 POMGNT1 
(Without CNS involvement)
Merosin-deficient classic type AR 6q2 Laminin-α2(merosin)
Integrin-deficient CMD AR 12q13 Integrin-α7
Distal muscular dystrophies
Late Adult Onset 1A(Wellander) AD 2p13    ?
Late Adult Onset 1B(Markesbery) AD 2p ?
Early Adult Onset 1A(Nonaka) AR 9p1-q1 GNE
Early Adult Onset 1B(Miyoshi) AR 2q12-14 Dysferin 
Early Adult Onset 1C(Laing) AD 14q ?
Other dystrophies
Facioscapulohumeral AD 4q35 ?
Oculopharyngeal AD 14q11 Poly(A) binding protein2
Myotonic dystrophy type1 AD 19 DMPK gene
Myotonic dystrophy type 2 AD 3q21 ZNF9
Other protein deficiencies have also been identified in
LGMD patients such as sarcoglycans, dysferlin and
calpain, which are classified as “sarcoglycanopathy,”
“dysferlinopathy”and “calpainopathy”. Despite
recent advances in molecular genetics, it is difficult to
assign an accurate and clinically useful classification
to the various muscular dystrophies.
The Dystrophin-Glycoprotein Complex 
The discovery of dystrophin and related molecules
has been crucial to the understanding and diagnosis
of a large group of muscular dystrophies.6, 7 A
schematic figure of the dystrophin-glycoprotein com-
plex (DGC) is shown in Fig. 1. 
The proteins initially were referred to as dystrophin-
associated proteins (DAPs) or dystrophin-associated
glycoproteins (DAGs). The DGC include several pro-
teins on the cytoplasmic side (e.g. dystrophin, syn-
trophins, and dystrobrevin) and two transmembrane
glycoprotein sub-complexes (dystroglycans and
sarcoglycans) (Table 2). Dystrophin is a large
rod-shaped cytoskeletal protein that binds F-actin.4
The dystroglycan complex is composed of α- and
β-dystroglycan (156 and 43 kDa) derived by the pro-
teolytic processing of a single precursor protein.8
β-dystroglycan binds at the cysteine-rich region of
dystrophin and is linked to α-dystroglycan on the
external side of the sarcolemma. Outside the muscle
fiber, α-dystroglycan is highly glycosylated and binds
to the α2-laminin subunit of laminin-2 (merosin).
Syntrophins are intracellular proteins that directly bind
to the C-terminus of dystrophin.9 The sarcospan is a
four transmembrane domain protein.10 The sarcogly-
can complex is composed of four (α, β, γ, and δ) pro-
teins with a single transmembrane domain, a relative-
ly small intracellular domain, and a large extracellular
domain. The recently identified ε-sarcoglycan is
expressed ubiquitously in many tissues, and may
have a different function.11 Only α-sarcoglycan has an
extracellular N-terminus. F-actin and laminin-2 inter-
act with the DGC, providing important continuity from
the intracellular cytoskeleton to the extracellular
matrix of the muscle fiber, which yields membrane
stability. Dystrophin and its molecular associates are
tightly associated and form an essential cytoskeletal
system at the muscle fiber surface membrane.6 The
complex is critical for maintaining the integrity of the
sarcolemma and muscle fiber.12 The functions of dys-
trophin and its associated complex are not fully
understood. In skeletal muscle, the most probable
role of the complex is mechanical reinforcement of
the sarcolemma and signal transduction.13, 14 The
DCG tightly connects intracellular cytoskeletal F-actin
to the extracellular matrix, thus forming the following
linkage: F-action-Dystrophin-Dystroglycan &
Sarcoglycan complex-Lamin2-Extracellar Matrix,
which serves as a “bolt”or “nut”for maintaining the
integrity of the sarcolemma. Muscle fibers containing
a mutation of the dystrophin gene, dystrophin-defi-
ciency, or dystrophin-loss are vulnerable to injury dur-
ing contraction and relaxation due to a loss of
cytoskeletal integrity, which leads to fiber necrosis,
regeneration, and clinically observed progressive
muscular weakness. Not only in dystrophinopathy,
but also in LGMD (sarcoglycanopathy) and CMD, the
result of DCG breakdown is the membrane instability
of muscle fibers and the manifestation of muscle
weakness (Fig. 2). 
However, many other myopathies were caused by
not only sarcolemma protein loss, but also by loss of
sarcomeric proteins, nuclear associated proteins,
enzymes, or other mechanisms (Table 3).
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Figure 1. Dystrophin-glycogrotein complex
The Dystrophinopathy: Duchenn and Becker
Muscular Dystrophy
DMD and BMD are X-linked allelic myopathies
caused by dystrophin deficiency, characterized by
progressive muscular weakness and degeneration of
skeletal muscle. DMD is the most common X-linked
recessive lethal myopathy with an incidence of 1 in
3500 newborns, whereas BMD has a frequency of
about 5 per 100,000, for a combined incidence of 1 in
3,000. It has been estimated that approximately one
third of the cases result from new mutations.15,16
Clinical symptoms of the DMD are observed after 2-3
years of age. Most affected boys exhibit retarded
motor development, with approximately half of them
failing to walk until the age of 18 months. Other early
onset characteristics include an unusual waddling
gait, difficulties with running and jumping, lumbar lor-
dosis, and calf enlargement.15,16 Weakness and wast-
ing of muscle are progressive and symmetrical,
affecting the lower limbs before the upper limbs, and
the proximal muscles before the distal muscles. Joint
contractures are an important clinical manifestation,
and by the age of 6 years most patients have con-
tractures at the iliotibial bands, hip joints, and heel
cords. Regenerating fibers become less abundant as
the disease progresses and are eventually replaced
by adipose and connective tissues, accounting for the
pseudohypertrophic muscles. The affected children
are usually wheelchair-bound by 12 years of age. As
the disease progresses, the contractures develop fur-
ther, leading to asymmetrical spinal deformities. Most
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Table 2. The Dystrophin-glycoprotein Complex (DGC)
I. Glycoprotein complex 
A) dystroglycan complex
α-dystroglycan (156DAG): a large extra-cellular laminin-binding glycoprotein 
β-dystroglycan (43DAG): a transmembrane glycoprotein 
B) sarcoglycan complex (SGC)
α-sarcoglycan (50DAG, adhalin): a transmembrane glycoprotein 
β-sarcoglycan (43DAG): a transmembrane glycoprotein 
γ-sarcoglycan (35DAG): a transmembrane glycoprotein 
δ-sarcoglycan (35DAG): a transmembrane glycoprotein 
ε-sarcoglycan: : a transmembrane glycoprotein 
II. Cytoplasmic complex 
syntrophin-complex
αl-syntrophin (59DAP), an acidic intra-cellular fairly muscle-specific protein 
β1-syntrophin (59DAP), a basic ubiquitously expressed protein 
β2-syntrophin (59DAP), a basic protein localized at the NMJ 
dystrobrevin : α-dystrobrevin, β-dystrobrevin 
III. Others 
dystrophin
sarcospan: (25DAP): a transmembrane protein 
unclassified: a large F-actin binding intra-cellular protein 
Figure 2. A schematic of the dystrphin-gylcoprtein complex
(DGC). (DMD; Duchenne muscular dystrophy, LGMD;
Limb-girdle muscular dystrophy, CMD; congenital muscular
dystrophy)
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Nomenclature
Dystrophinopathy (DMD/BMD)
LGMD2C, 2D, 2E, 2F
LGMD1C
LGMD2B
ITGA7
Congenital muscular dytrophy (MDC1A)
UCMD/Bethlem Myopathy
LGMD2A
Fukuyama CMD
MDC1C/LGMD2I
MEB
WWS
LGMD2H
HIBM/DMRV
LGMD1A
LGMD2G
LGMD2J
EDMD
EDMD1/LGMD1B
Oculopharyngeal muscular dystrophy
RSMD1
MD + epidermolysis Bullosa
Myotonic dystrophy type 1
Myotonic dystrophy type 2
Fascioscapulohumeal dystrophy
Proteins of molecular defects
Sarcolemma associated
Dystorphin
Sarcoglycans (α,β,Y,δ)
Caveolin
Dysferlin
Integrin α7
Extracellular Matrix
Laminin 2 chain
Collagen 6A1, A2, A3
Proteins with enzymatic activity
Calpain 3
Fukutin
Fukutin Reated protein
POMGnT1
POMT1
TRIM 32
GNE
Saromeric proteins
Myotilin
Telethonin
Titin
Nuclear associtated proteins
Emerin
Lamin A/C
PAB2
Others
Selenoprotein N
Plectin
Repeat expansion disease
DMPK-CTG repeat
ZNF9-CCTG repeat
Large telemetnic deletion
Deletion of D4Z4 repeat
Muscular Dystrophy Classification with Molecular Defect
Table 3. Muscular dystrophy classification with molecular defect
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patients die at approximately age 20 of pneumonia
related to chronic respiratory insufficiency. Cardiac
involvement is a consistent part of DMD. As many as
90% of DMD patients show electrocardiogram abnor-
malities.17 The heart exhibits fibrosis in the poster-
obasal portion of the left ventricular wall. Defects in
the intra-atrial conduction system are more common
than atrioventricular and infranodal disturbances.
Despite a known predisposition to cardiac disease,
most patients with DMD remain surprisingly free of
cardiovascular symptoms. Approximately 20% of
affected patients will be mentally handicapped. The
impairment of intellectual function appears to be non-
progressive and affects verbal ability more than per-
formance.18 BMD has a milder clinical course and a
slower disease progression.19 The majority of BMD
patients initially experience difficulties between 5 and
15 years of age, although onset in the third or forth
decade of age, or even later, can occur. By definition
the affected patients remain ambulant until 16 years
of age or later, thus allowing the clinical distinction
from patients with DMD. Patients with BMD have a
reduced life expectancy, but the majority of patients
survive into at least the forth or fifth decade. A
well-recognized subgroup of patients with an interme-
diate course between those typical of Duchenne and
Becker dystrophies are referred to as intermediate
patients or outliers.20 These patients can usually be
recognized by the age of 3 years via the relative
preservation of strength in neck flexion (anti-gravity
neck flexor muscles), whereas patients with DMD
lack this ability throughout their entire life.
Intermediate patients retain the ability to climb stairs
and walk (after the age of 12, but not beyond 15
years) longer than patients with typical DMD. 
The gene for DMD/BMD, dystrophin, was identified
by positioning cloning in 1988.21, 22 The dystrophin
gene is one of the largest human genes identified,
spanning more than 2000 kb of genomic DNA, and is
composed of 79 exons that encode a 14-kb tran-
script.23, 24 It is localized at the short arm of the X chro-
mosome (Xp21.1). The dystrophin gene produces
several isoforms of dystrophin.25 The molecular
weight of full-length dystrophin is 427 kd. Four distinct
domains have been defined: 1) an amino terminus
that associates with actin or an actin-like protein, 2) a
rod domain consisting of long flexible rows of 24
α-helical repeats, 3) a cysteine-rich region, and 4) a
unique carboxy terminus. Dystrophin tightly associ-
ates with a large oligomeric complex of sarcolemmal
glycoproteins through its cysteine-rich domain and
carboxy-terminus, whereas the amino-terminal
domain interacts with actin or an actin-like protein.26, 27
In dystrophinopathies, the absence of dystrophin
leads to a secondary reduction in all components of
the DGC and disruption of the DGC. Dystro
phinopathies cover a wide range of clinical severity
(presenting symptom, age of onset and rate of pro-
gression) as mentioned above. The simplest explana-
tion for this phenotype variation is mutations of the
“reading frame rule”in protein translation. In-frame
deletions produce smaller, semi-functional proteins,
while frame shifting deletions generally produce a few
incorrect amino acids before a premature stop codon
is generated. There are exceptions to this reading
frame rule. Complete dystrophin deficiency may be
associated with a relatively benign phenotype. The
amount, quality, and even distribution of dystrophin
and the region of exon deletion are functionally
important. Mutations in the dystrophin gene are not
randomly distributed, but occur at two particular
hotspots with about 30% occurring at a proximal
hotspot.
The pathological findings in dystrophinopathy are
increased variation in fiber size, evidence of fiber
necrosis with phagocytosis, hypercontracted
eosinophilic hyaline fibers, some centrally nucleated
fibers, and increased connective tissue (Fig. 3).
Immunostaining of muscle sections with antibodies to
dystrophin is essentially negative in DMD patients,
whereas in BMD patients staining is decreased or
interrupted (Fig. 4).28 A patch staining, similar to that
seen in BMD muscle, is also observed in other mus-
cle disorders as well as in symptomatic carriers of
dystrophinopathy (Fig. 4).29 Western blot analysis for
dystrophin is particularly useful in BMD patients
because bands of abnormal size and low amounts
are easily detected.
Limb-girdle Muscular Dystrophy (LGMD)
Limb-girdle muscular dystrophies (LGMD) are clini-
cally and genetically heterogeneous muscle disor-
ders, characterized by a progressive weakness and
muscle wasting of the pelvic and shoulder-girdle,
ranging from severe forms with onset in the first
decade and rapid progression to milder forms with
later onset and a slower course.30 The term ‘limb-gir-
dle dystrophy’was introduced by Walton and
Nattrass in 1954.31 From the clinical viewpoint, LGMD
refers to patients not fitting into one of the defined
muscle disorders with typical clinical feature such as
DMD/BMD, FSHD, and myotonic dystrophy. The
recent advances in understanding the molecular
pathogenetic mechanism of LGMD have made possi-
ble a genetic classification based on the molecular
defect from the clinical classification. By now, more
than 16 of LGMD subtypes have been identified.
LGMD1 refers to the autosomal mutation dominantly
inherited, while LGMD2 consists of disorders with
autosomal recessive transmission.
Autosomal dominant LGMD (LGMD1)
Autosomal dominant LGMD (LGMD1) is a hetero-
geneous group of disorders. LGMD1 is a relatively
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Figure 3. Section from muscle biopsies taken from patients with Dystrophinopathy (Right; Gomoritrichrome staining, left; H&E stain-
ing)
Figure 4. Immunostaining of muscle sections with antidystrophin antibodies.(right; normal, middle; dystrophinopathy, left; manifest-
ed carrier in female)
small proportion of all LGMD patients, less than 10%.
There are to date, at least six autosomal dominant
forms of LGMD which have been assigned to chro-
mosomal loci or genes (Table 4).
LGMD1A is called “myotilinopathy”and is assigned
to chromosome 5q31, the gene locus that codes for
myotilin.32 The disease is characterized by onset at
the age of 42-77 years with an initial muscle weak-
ness in distal or proximal leg muscles, eventually
spreading to other muscle groups of the lower and
upper extremities. Associated signs of cardiomyopa-
thy, respiratory failure and peripheral neuropathy are
present in a fraction of patients. Myopathological fea-
tures of focal myofibrillar destruction resulting in intra-
cytoplasmic deposits, strong immunoreactivity to
myotilin, multiple rimmed and centrally or subsar-
colemmally located non-rimmed vacuoles, and
streaming Z-lines were observed in each patient stud-
ied.33
LGMD1B, due to LMNA gene mutations, is a rela-
tively rare form of LGMD characterized by proximal
muscle involvement associated with heart involve-
ment comprised of atrioventricular conduction blocks
and dilated cardiomyopathy.34 Mutations in the lamin
A/C gene have been reported in a variety of disorders
including autosomal dominant Emery-Dreifuss mus-
cular dystrophy (AD-EDMD) and LGMD1B. AD-
ADMD is characterized by early contractures of
elbows and Achilles tendons, and a humero-peroneal
distribution of weakness combined with cardiomyopa-
thy with conduction defects. LGMD1B and AD-EDMD
are allelic disorders.35 
LGMD1C (caveolinopathy), a third dominant form
was identified by mutations in the caveolin-3 gene
(CAV3) located at 3p25, encoding caveolin-3, the
muscle-specific form of the principal protein compo-
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Autosomal Dominant 
LGMD1A
LGMD1B
LGMD1C
LGMD1D
LGMD1E
LGMD1F
Autosomal Recessive
LGMD2A
LGMD2B
LGMD2C
LGMD2D
LGMD2E
LGMD2F
LGMD2G
LGMD2H
LGMD2I
LGMD2J
5q31 
1q11-21
3p25
6q23
7q
7q
15q15
2p13
13q12
17q21-q21
4q12
5q33
17q12
9q31-34
19q13.3
2q31
Disease Location Gene / Product Pathogenic Mechanism
Table 4. Classification of LGMD
MYOT / myotilin
LNMA/C / laminA/C
CAV3 / Caveolin-3
?
?
FLNC/Filamin
CAPN3 / Calpain-3
FER-1 / dyferlin
SGCC /γ-saroglycan
SGCA /α-saroglycan
SGCB /β-saroglycan
SGCD /δ-saroglycan
TCAP / Telethonin
TRIM32
FKRP
Titin
?
?
Abnormal oligomerization of caveolins
?
?
Inability of mutant protein to dimerization 
Loss of proteolytic activity
Abnormal membrane repair
Abnormal membrane integrity
Abnormal membrane integrity
Abnormal membrane integrity
Abnormal membrane integrity
Abnormal saromeric z-line assembly
?
Defective glycosylation of γ-dystrolycan
Abnormal saromeric assembly
nent of caveolae in the plasma membrane. This form
is the most common in LGMD1, characterized by
proximal weakness of predominantly leg muscle
associated with cardiac arrhythmia and dilated car-
diomyopathy. The age of onset is 4-38 years. Slow
progression of weakness and hypertrophic calf mus-
cle are noted. The sarcolemma localization of cave-
olin-3 is linked to a complex pathway where oligomer-
ization occurs in the Golgi apparatus (a possible
dominant negative mechanism). Immunostaining with
anti-caveolin-3 was reduced 90-95%. Dystrophin and
sarcoglycan staining was only slightly affected.36
Autosomal recessive LGMD (LGMD2)
Autosomal recessive LGMS is a heterogeneous
group of disorders, which include at least ten different
genetic entities (Table 4). The first LGMD2, LGMD2A,
was mapped to 15q in 1991.37 and nine additional
forms of AR-LGMD have also been mapped. The
protein products of these ten genes have been identi-
fied (Table 4). They are: calpain-3 for LGMD2A,38 dys-
ferlin for LGMD2B,39,40 α-sarcoglycan (SG) for
LGMD2D,41,42 β-SG for LGMD2E, 43,44 γ-SG for
LGMD2C,45,46 δ-SG for LGMD2F,47 the sarcomeric pro-
tein telethonin for LGMD2G,48 TRIM32 for LGMD2H,49
fukutin-related protein (FKRP) for LGMD2I,50 and titin
for LGMD2J.51
1) LGMD2A (Calpainopathy)
LGMD2A, calpainopathy, was the first form of
limb-girdle dystrophy identified that is caused by a
deficiency of a non-structural protein, the enzyme cal-
pain 3. Calpain 3 (p94) is a calcium-dependent pro-
tease that may be implicated in the contractile
process since it can bind strongly to titin.52
Demonstration of the involvement of muscle-specific
calcium-activated neutral protease 3 in LGMD2A was
the first example of an enzymatic rather than a struc-
tural protein defect causing a progressive muscular
dystrophy. Calpainopathy is the most frequent form of
LGMD, accounting for about 30% of the identified
cases. Clinically, LGMD2A is characterized by sym-
metrical and selective proximal atrophy with no car-
diac or facial disturbance and normal intelligence.
However, the course is highly variable.53 A wide intra
and interfamilial clinical variability ranging from
severe to mild forms was reported.54 The mean age at
onset was 13.7 years (ranging from 2 to 40 years),
and the mean age at loss of walking ability was 17.3
years (range 5-39 years) after onset with no sex dif-
ference between the age at onset or progression.
Calf hypertrophy and elevated serum creatine kinase
(CK) has been reported. Serum CK levels are higher
than normally observed, yet not as elevated as
observed in dystrophinopathies or sarcogly-
canopathies. The calpain 3 gene in chromosomal
region 15q15 is comprised of 24 exons and covers a
genomic region of 50 kb. It is expressed as a 3.5 kb
transcript, and a 94 kDa translated protein. To date,
more than 140 different mutations have been
described.55 Muscle pathology shows marked varia-
tions in fiber size with necrotic and regenerating
process and interstitial fibrosis. One of the striking
findings in the later stages of calpainopathy is an
abnormal lobulation of type 1 fibers after staining with
NADH-tetrazolin reductase. Immunocytochemical
studies show normal sarcolemmal labeling with dys-
trophin, utrophin and sarcoglycan antibodies.
Because of the instability of calpain-3 in muscle, pro-
tein immunostaining is not a reliable diagnostic mea-
sure for detecting calpainopathy. Direct mutation test-
ing must be performed in order to diagnose calpain-
opathy through molecular methods. Although not a
definitive method, western blot detection calpain-3
protein in muscle is nevertheless an easy and useful
method for the primary screening of calpainopathy.55
The analysis of calpain-3 in other forms of muscular
dystrophy revealed no apparent alteration in sarco-
glycanopathy or telethoninopathy patients.56,57
However, a secondary reduction of calpain-3 was
reported in LGMD2B patients, suggesting a possible
association between calpain-3 and dysferlin.56,58,59
Subsequently, other studies have shown a secondary
reduction of calpain-3 in other forms of LGMD such
as LGMD2I and LGMD2J, which requires further
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studies.51,60  
2) LGMD2B (Dysferlinopathy) 
LGMD type 2B (LGMD2B) is caused by mutations
in the dysferlin gene (DYSF) located on chromosome
2p13.3, which induces a dysfunction of dysferlin at
the protein level.40 Dysferlin is a member of the FER-1
protein family and contains six putative C2 domains,
which can bind to phospholipids, inositol polyphos-
phates, Ca2+, and intracellular proteins.61 Dysferlin is
expressed predominantly in the skeletal muscle and
localizes to the plasma membrane of muscle fibers.
In addition, it has been suggested to be involved in
membrane fusion.62,63 A recent animal study has sug-
gested that dysferlin plays a role in the sarcolemma
repair process.64 DYSF has been also shown to
cause Miyoshi myopathy, which is a rare form of dis-
tal myopathy characterized by calf muscle weakness.
Both LGMD2B and Miyoshi myopathy are referred to
as “dysferlinopathy”because of the deficiency of the
same protein. 
The clinical spectrum may present with myalgia,
high CK, or difficulty walking on tip toes. The disease
generally manifests during the early adulthood (aver-
age onset is noted between the age of 17-30 years),
and the disease generally has a benign course, with
confinement to a wheelchair occurring in approxi-
mately 10% of patients.65,53 Despite the slow clinical
evolution, an extremely high CK level (10-20 times
the normal value) is characteristic of LGMD2B, being
indicative of the protein’s role in normal muscle
homeostasis (“leaky”membrane) rather than being
essential for structural stabilization of the skeletal
muscle.66,67 The proportion of LGMD2B is thought to
be relatively high in Brazilian and Japanese popula-
tions (estimated to be 19-25% of all ARLGMD
cases).65,68 Moreover, the founder mutation of DYSF
appears to be present in a population of Libyan
Jews.69 However, another recent study reported a rel-
atively lower frequency of dysferlin deficiency in
Caucasian patients with the LGMD phenotype
(approx. 1%), indicating a frequency variation accord-
ing to population ethnicity.70 Although insufficient to
estimate the frequency of LGMD2B in Korean ARL-
GMD patients due to their small number, the frequen-
cy of LGMD2B might be relatively high among ARL-
GMD patients in Korea.71 A detailed population-based
study will be needed to determine the exact frequen-
cy of LGMD2B in Korea. The dysferlin gene, DYSF, is
relatively large, comprising 55 exons that span a
genomic region of > 150kb.72 Although direct gene
analysis provides the most reliable diagnosis, it is
costly, time-consuming, and labor intensive because
of the large size of the DYSF. Moreover, defects in
the dysferlin gene involve mostly single nucleotide
changes with no common mutations, gross
rearrangements, or mutational hotspot that could aid
detection.73 For this reason, it would be better to initi-
ate screening for dysferlin deficiency using antibodies
against this protein in muscle biopsies. Complete loss
of dysferlin without deficiency of other proteins
appears to be specific for primary dysferlinopathy as
observed by immunocytochemistry.73 
Muscle biopsy shows non-specific myopathic
changes that include marked variation in fiber size,
centrally situated nuclei, fiber splitting, scattered
necrotic and regenerating fibers, and an occasional
perivascular infiltrate comprised of lymphocytes and
macrophages. There is increased connective tissue
in the endomysium and perimysium. Fiber type distri-
bution is normal, while rimmed vacuoles and ragged
red fibers are absent. 
The molecular diagnosis of dysferlinopathy by pro-
tein analysis is now easily available. The pattern of
immunostaining against dysferlin antibody is either
completely absent or markedly reduced. It is notewor-
thy that a recent study has found reduced dysferlin
immunoreactivity in about half of sarcoglycanopathies
and 20% of dystrophinopathies examined, indicating
that diminished dysferlin expression could be due to
secondary processes related to muscle cell degener-
ation.74 
3) LGMD2C-F (Sarcoglycanopathy)
Mutations in the genes encoding the sarcoglycan
proteins (α, β, γ, and δ) (primary sarcogly-
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canopathies) have recently been shown to cause
some cases of genetically heterogeneous autosomal
recessive muscular dystrophies (limb-girdle muscular
dystrophy types 2D, 2E, 2C, and 2F, respectively).75
Sarcoglycans are transmembrane proteins within the
DGC, and are of unknown function.7,75-77 A fifth sarco-
glycan (ε-sarcoglycan), has recently been identified
through its homology to α-sarcoglycan, and its gene
has been mapped to chromosome 7q21.11 It is not
yet known to be involved in any muscle disorders.
The pathogenesis of the sarcoglycanopathies is
likely very similar to that of dystrophinopathy, as both
involve the loss of DGC integrity. Loss of the sarco-
glycans leads to membrane instability, with conse-
quent efflux of cytoplasmic components, such as
serum kinase out of the myofiber, and an influx of cal-
cium and other material into the cell.78 As loss or defi-
ciency of any one of the four sarcoglycans causes
muscular dystrophy, these proteins must play a criti-
cal role in the maintenance of membrane integrity.
Patients with a primary sarcoglycanopathy are clini-
cally indistinguishable from those with primary dys-
trophinopathies. Sarcoglycanopathies show a wide
spectrum of clinical severity. α-sarcoglycanopathy
patients typically show missense mutation, which can
vary from Duchenne-like to asymptomatic. The other
sarcoglycanopathies (β, γ, and δ) show a higher fre-
quency of deletion mutation, which leads to complete
loss of the corresponding proteins and severe pheno-
type. All patients presented with proximal weakness,
elevation of serum creatine kinase, and calf hypertro-
phy. Cardiac involvement was variable.
The pathology of muscle in sarcoglycanopathies
shows a dystrophic myopathy, indistinguishable from
DMD/BMD. Light microscopic findings show degener-
ation and regeneration of muscle fibers, myofiber size
variation, increased number of central nuclei, and
endomysial fibrosis. Diagnosis was done by protein
analysis of a muscle biopsy using immunohistochem-
istry for the sarcoglycan proteins. Sarcoglycanopathy
patients show a dramatic reduction in all four sarco-
glycan proteins. Loss of any one of these sarcoglycan
proteins leads to the secondary reduction or absence
of others. Dystrophin protein can be normal or lead to
secondary reduction. Partial reduction of sarcoglycan
proteins observed by immunostaining is a less specif-
ic diagnosis for primary sarcoglycanopathy.
Therefore, multiple western blotting is useful for differ-
ential diagnosis in sarcoglycanopathies, DMD, and
female carrier DMD.
Fascioscapulohumeral Muscular Dystrophy
Facioscapulohumeral muscular dystrophy (FSHD)
has an estimated prevalence of one in 20,000 peo-
ple, making it the third most common form of muscu-
lar dystrophy after Duchenne and myotonic muscular
dystrophy.79 FSHD, an autosomal dominant neuro-
muscular disease, was first described by Landouzy
and Dejerine in 1885. The majority of cases are famil-
ial. Sporadic cases resulting from de novo mutations
account for 10-30%.80,81 Characteristics of the disease
are the early involvement of facial and scapular mus-
cles with eventual spreading to the pelvic and lower
limb muscles, with the foot extensors often affected
earlier and more severely than pelvic muscles.
Because bulbar, respiratory, and cardiac functions
are generally spared, life expectancy is normal.
Eventually, 20% of patients become wheelchair-
bound.79 Another characteristic clinical feature is the
asymmetry in muscle weakness found prominently in
the face and shoulder girdle. Extramuscular manifes-
tations of FSHD include high frequency hearing loss,
retinal telangiectasias, and predisposition to atrial
arrhythmias.82 In 1990, linkage to a marker on chro-
mosome 4q 35, p13E-11, was found. Subsequently,
affected people were shown to carry a small EcoRI
fragment detected by p13E-11 (Fig. 5).83 Normal indi-
viduals have 11 or more repeats on chromosome
4q35, whereas individuals with FSHD have 10 or
fewer repeats on one copy of 4q35.84 The diagnosis of
FSHD can be confirmed by DNA restriction fragment
analysis in 95% of patients.85 An EcoRI fragment size
below 38 kb is compatible with a diagnosis of
FSHD.86 Although the size of the small fragment cor-
relates inversely with disease severity, the exact rela-
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tionship of the fragment to the pathogenesis of the
clinical disease is unclear. FSHD is currently untreat-
able. Few therapeutic trials of this disorder have been
conducted. 
Myotonic Dystrophy
Myotonic dystrophy (dystrophia myotonia, DM) is
the most common inherited muscle disorder in
adults.87 DM is an autosomal dominant degenerative
disease of the skeletal muscle, heart, eyes, endocrine
system, central and peripheral nervous systems, gas-
trointestinal organs, bone, and skin. The most char-
acteristic feature is muscle weakness and wasting
with myotonia that begins in the distal limb and cra-
nial muscle. The prevalence is 5/100,000 and the
incidence is about 13.5/100,000 live births. Based on
its genetic locus and clinical features, DM is subclas-
sified as myotonic dystrophy 1 (DM1) and myotonic
dystrophy 2 (DM2, or PROMM). The genetic basis for
DM1 is an expansion of an unstable cytosine-
thymine-guanine (CTG) trinucleotide repeat in the 3'
untranslated region of the myotonic dystrophy protein
kinase (DMPK) gene in chromosome 19 (Fig. 6).88
Normal DMPK alleles have 4 to 37 CTG repeats,
whereas DM1 alleles have 50 to more than 4000
repeats. Longer expansion correlates with earlier
symptom onset and a more severe disease. The size
of the expanded repeat and the severity of the dis-
ease tend to increase in successive generations
(anticipation). DM1 is divided into congenital and
classical phenotypes according to the age of symp-
tom onset and disease severity. The first symptom is
usually grip myotonia that begins in the second, third,
or fourth decade. The earliest signs of weakness can
be found in the finger flexor, neck flexor, and facial
muscle. Muscles of the proximal limb and limb girdle
are affected later. The signs at presentation are pto-
sis, facial weakness, temporalis wasting, and weak-
ness of the neck and distal muscle. The extramuscu-
lar features of DM are related to the heart (conduction
defect, arrhythmia), smooth muscle (impaired intesti-
nal motility and uterine contractility), lens (cataract),
brain (mental retardation, hypersomnolence, and
neuropyschiatric manifestation), and endocrine regu-
lation (testicular atrophy, insulin resistance, and
abnormal growth hormone release). The heart-relat-
ed features are progressive fibrosis of the conduction
system and abnormal excitation. Cardiac arrest due
to heart block or ventricular tachyarrhythmia is a com-
mon cause of death. Approximately 10% of patients
with congenital DM1 present in infancy with neonatal
hypotonia, feeding and respiratory difficulties, and
mental retardation survive into childhood. Infants with
congenital DM1 have very large repeat expansions
(>1000 CTG repeats). In 1994, Thornton et al.89
described an autosomal dominant disorder similar to
DM without CTG repeat expansion at the DMPK.
Ricker et al.90 named this disease “proximal myotonic
myopathy” because proximal muscle weakness with-
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Figure 5. The FSHD region gene. In normal, the D4Z4 (Kpnl
unit) repeat unit contain more than 11(more than 35 kb). In
FSHD, this fragment is reduced to the fewer than 10 repeat,
less than 35 kb.
Figure 6. The DM1 locus. the DTG repeat in DM1 is increased
more than 50.
out atrophy was observed predominantly as opposed
to the distal muscle involvement seen in DM1.
Because of the close phenotypic resemblance to DM,
this disease was called “myotonic dystrophy type 2”.
In 1998, Ranum et al.91 assigned the DM2 locus to
chromosome 3q. DM2 is caused by a CCTG expan-
sion (mean approximately 5000 repeats) located in
intron one of the zinc finger protein 9 (ZNF9) gene.92
The histopathology of DM1 is characterized by atro-
phy of muscle fibers and abnormality of the myonu-
clei. Furthermore, type 1 fiber atrophy with type 2
fiber hypertrophy, increased numbers of centrally
located nuclei occurring as chains (chained nuclei)
within muscle fibers, ringed fibers with sarcoplasmic
masses, and pyknotic nuclear clump are observed.
DNA testing for the diagnosis of DM has been avail-
able since the discovery of the expanded CTG or
CCTA repeat as the genetic mutation. PCR based
estimation of repeat number or southern blotting is
now the standard approach for detecting trinucleotide
expansions.93
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국문요지
근이양증 (muscular dystrophy)는 임상적으로는 유전적인
요인으로 진행성 근력저하를 보이고, 근병리적으로는 근섬유의
괴사 및 재생을 특징으로 하는 퇴행성 근육질환이다. 근이양증
중 발병년령과 침범 부위의 특징에 따라서 선천성 근이양증
(congenital muscular dystrophy), Duchenn형 근이양증
(Duchenne muscular dystrophy, DMD), Becker형 근이양증
(Becker muscular dystrophy, BMD), 지대형 근이양증
(Limb-girdle muscular dystrophy), 안면견갑상완 근이양증(fas-
cioscapulohumeral muscular dystrophy), 근긴장성 이양증
(myotonic dystrophy) 등으로 구분하게 되었고 이 분류가
지금까지도 사용하고 있다. 1980년대의 분자생물학의 발달로
근세포막에 존재하는 단백질 및 그 유전자의 연구가 활발하게
진행되어 1986-7년“dystrophin 유전자”가 발견되고 이 유전자
돌연변이(mutation)에 의해서 dystrophin 단백이 소실되어
DMD 및 BMD가 발병하는 것이 밝혀졌다. 그 후 여러 연구자에
의해서 근세포막에 존재하는 다른 단백질을 발견하게 되었고,
그 유전자 변이가 또 다른 형의 근이양증의 원인이 된다는 것도
밝혀졌다. 더 나가서 같은 유전자 변이에 의해서 생긴 병이라도
표현형이 다른 근육질환이 발생할 수도 있다는 것도
발견되었다. 그 결과 근이양증은 원인 유전자와 단백질에 따라
분류가 좀더 세분화되고, 명칭도 변화되고, 새로운 원인유전자
들이 발견되고 있다. 따라서 향후 근이양증에 대한 분자유전
학적 병인이 더 많이 밝혀질 것이고, 근육질환의 분류도 변화할
것으로 생각된다.
중심단어: 근이양증, dystrophin-glycoprotein 복합체, 지대 형
근이양증, 안면견갑상완 근이양증, 근긴장성 이 양증
